New Guide Provides Information on Benefits of Multidisciplinary Care for ALS Treatment

Anti-epilectic Compound Shows Neuroprotective Effects in ALS Worm Model, Study Reports

The active molecule of Petinutin (methsuximide), an anti-epileptic medication, eased motor deficits, extended the lifespan, and showed potent neuroprotective effects in a worm model of amyotrophic lateral sclerosis (ALS), suggesting a potential new treatment strategy for multiple neurodegenerative diseases, a study reports. The study, “α-Methyl-α-phenylsuccinimide ameliorates neurodegeneration…

Stumbling Upon an ALS-free Zone

“Hope is the thing with feathers” –Emily Dickinson Recently, my wife and I went to see a stand-up comedian at our local indoor stadium. My fervent hope was that our evening together would be a unifying, restorative one. It was in that spirit that we performed all of the mental and…

When ALS Becomes a Hard Act to Swallow

Swallowing. It’s such a simple thing to do! We’re born with the ability to swallow; it happens automatically, and the average person does it approximately 600 times a day. I mean, who actually thinks about swallowing? Well, I do, now that I’ve joined the nearly 80…

Right to Try vs. Right to Say No: An Open Letter to Lawmakers

Dear Congress, The recently enacted federal Right to Try Law (RTT) is really a “Right to Ask” law. And, for the pharmaceutical companies, it’s a “Right to Say No.” Which they certainly almost always will. Case in point: BrainStorm Cell Therapeutics pre-emptively announced that NurOwn, its ALS stem cell treatment candidate,…

Phase 3 Trial of Oral Levosimendan as Respiratory Treatment for ALS Recruiting in US, Europe and Australia

A new Phase 3 trial evaluating levosimendan (also known as ODM-109), an oral treatment by Orion for breathing problems in amyotrophic lateral sclerosis (ALS), has recruited its first patients, the Finnish pharmaceutical company announced. The trial, called REFALS (NCT03505021), aims to investigate the potential benefits of prolonged treatment with levosimendan…